NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Pulmonx Corporation (LUNG) Stock Analysis

Pulmonx Corporation (LUNG) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LUNG

$1.83

+$0.01 (+0.55%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LUNG with… →

LUNG Key Statistics

As of Oct 21, 2026
Trading
Open
$1.82
Previous Close
$1.82
Day's Range
1.82–1.86
52-Week Range
1.13–2.89
Volume
176.67K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.34
Valuation
Market Cap
$78.60M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.90
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.15
Financials (FY)
Revenue (FY)
$90.50M+8.01%
Net Income (FY)
−$54.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−55.03%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.95M
1-Year Return
+13.66%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
493.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LUNG closed at $1.83, +13.66% over 1 year.

Pulmonx Corporation (LUNG) has a market capitalization of $78.60M.

In fiscal 2025, LUNG reported revenue of $90.50M.

LUNG Stock Return by Calendar Year

Pulmonx Corporation (LUNG) return since Oct 2020: what $10,000 became

1 year
$10,000 $11,366
+13.66%
5 years
$10,000 $462
−95.38%
Since Oct 2020
$10,000 $466
−95.34%

If you had invested $10,000 in Pulmonx Corporation (LUNG) at the close on October 1, 2020, the earliest close on record here, it would have been worth $466 at the close on October 21, 2026: −95.34% in total, −39.75% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.19%
2025−67.45%
2024−46.75%
2023+51.25%
2022−73.71%
2021−53.54%
2020 (partial year)+75.58%

As of October 21, 2026.

LUNG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$90.50M−$54.00M−59.7%
2024$83.79M−$56.39M−67.3%
2023$68.68M−$60.84M−88.6%
2022$53.66M−$58.92M−109.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$90.50M$67.14M−$53.66M−$54.00M−59.7%
2024$83.79M$62.00M−$57.70M−$56.39M−67.3%
2023$68.68M$50.75M−$61.94M−$60.84M−88.6%
2022$53.66M$39.87M−$58.64M−$58.92M−109.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LUNG Valuation vs Medical Devices Median

Median of 145 stocks
MetricLUNGMedical Devices medianvs median
P/S ratio0.902.5364% below
Profit margin−55.03%−14.78%40.2 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Pulmonx Corporation (LUNG) at $78.60M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 296 employees.

Over the past 52 weeks the price has ranged from $1.13 to $2.89. The most recent close on file for LUNG is $1.83, dated October 21, 2026. That is +$0.01 (+0.55%) against the previous close. The latest close sits 61.95% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $90.50M. Against the prior fiscal year total of $83.79M, that is a change of +8.01%. The same year closed with a net loss of $54.00M. Profit margin runs at −55.03%. That is 40.2 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −1.15.

Across the 4 fiscal years on file, revenue moves from $53.66M in 2022 to $90.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.9. On price-to-sales that is 64.47% below the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

The reported beta is 0.34. Daily returns over the trailing 6 years annualize to a volatility of 79.16%. The trailing one-year total return is +13.66%. Across 5 years the annualized return works out at −45.94%.

Growth & Income

No dividend is on file for LUNG.

So far in 2026 the total return is −17.19%. Across the complete calendar years on file, 2023 returned +51.25% and 2022 returned −73.71%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Pulmonx Corporation (LUNG) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pulmonx Corporation LUNG $78.60M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Pulmonx Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pulmonx Corporation

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Visit website →